Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 4
2020 3
2022 4
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?
Incorvaia L, Perez A, Marchetti C, Brando C, Gristina V, Cancelliere D, Pivetti A, Contino S, Di Giovanni E, Barraco N, Bono M, Giurintano A, Bazan Russo TD, Gottardo A, Cutaia S, Pedone E, Peri M, Corsini LR, Fanale D, Galvano A, Scambia G, Badalamenti G, Russo A, Bazan V. Incorvaia L, et al. Among authors: cutaia s. Cancer Treat Rev. 2023 Dec;121:102650. doi: 10.1016/j.ctrv.2023.102650. Epub 2023 Oct 31. Cancer Treat Rev. 2023. PMID: 37939446 Free article. Review.
Immuno-targeted combinations in oncogene-addicted non-small cell lung cancer.
Listì A, Barraco N, Bono M, Insalaco L, Castellana L, Cutaia S, Ricciardi MR, Gristina V, Bronte E, Pantuso G, Passiglia F. Listì A, et al. Among authors: cutaia s. Transl Cancer Res. 2019 Jan;8(Suppl 1):S55-S63. doi: 10.21037/tcr.2018.10.04. Transl Cancer Res. 2019. PMID: 35117064 Free PMC article. Review.
Navigating the liquid biopsy Minimal Residual Disease (MRD) in non-small cell lung cancer: Making the invisible visible.
Gristina V, La Mantia M, Peri M, Iacono F, Barraco N, Perez A, Viscardi G, Cutaia S, Russo TDB, Anwar Z, Incorvaia L, Fulfaro F, Vieni S, Pantuso G, Graceffa G, Russo A, Galvano A, Bazan V. Gristina V, et al. Among authors: cutaia s. Crit Rev Oncol Hematol. 2023 Feb;182:103899. doi: 10.1016/j.critrevonc.2022.103899. Epub 2022 Dec 31. Crit Rev Oncol Hematol. 2023. PMID: 36596401 Free article. Review.
Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer.
Fanale D, Brando C, Corsini LR, Cutaia S, Di Donna MC, Randazzo U, Filorizzo C, Lisanti C, Magrin L, Gurrera V, Romano R, Dimino A, Bazan Russo TD, Olive D, Vieni S, Pantuso G, Giordano A, Chiantera V, Russo A, Bazan V, Iovanna JL. Fanale D, et al. Among authors: cutaia s. BMC Cancer. 2023 May 13;23(1):437. doi: 10.1186/s12885-023-10911-5. BMC Cancer. 2023. PMID: 37179293 Free PMC article.
Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials.
Galvano A, Scaturro D, Badalamenti G, Incorvaia L, Rizzo S, Castellana L, Cusenza S, Cutaia S, Santini D, Guadagni F, Roselli M, Gori S, Latteri MA, Bazan V, Giulia LM, Russo A. Galvano A, et al. Among authors: cutaia s. J Bone Oncol. 2019 Jul 16;18:100252. doi: 10.1016/j.jbo.2019.100252. eCollection 2019 Oct. J Bone Oncol. 2019. PMID: 31440444 Free PMC article. Review.
The diagnostic accuracy of PIK3CA mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysis.
Galvano A, Castellana L, Gristina V, La Mantia M, Insalaco L, Barraco N, Perez A, Cutaia S, Calò V, Bazan Russo TD, Francini E, Incorvaia L, Mirisola MG, Vieni S, Rolfo C, Bazan V, Russo A. Galvano A, et al. Among authors: cutaia s. Ther Adv Med Oncol. 2022 Sep 26;14:17588359221110162. doi: 10.1177/17588359221110162. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 36188485 Free PMC article.
Can circulating PD-1, PD-L1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels enhance prognostic power of CA125 in patients with advanced high-grade serous ovarian cancer?
Fanale D, Corsini LR, Brando C, Cutaia S, Di Donna MC, Filorizzo C, Lisanti MC, Randazzo U, Magrin L, Romano R, Bazan Russo TD, Olive D, Vieni S, Pantuso G, Chiantera V, Russo A, Bazan V, Iovanna JL. Fanale D, et al. Among authors: cutaia s. Front Oncol. 2022 Sep 21;12:946319. doi: 10.3389/fonc.2022.946319. eCollection 2022. Front Oncol. 2022. PMID: 36212445 Free PMC article.
Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study.
Gristina V, Barraco N, La Mantia M, Castellana L, Insalaco L, Bono M, Perez A, Sardo D, Inguglia S, Iacono F, Cutaia S, Bazan Russo TD, Francini E, Incorvaia L, Badalamenti G, Russo A, Galvano A, Bazan V. Gristina V, et al. Among authors: cutaia s. Cancers (Basel). 2022 Dec 6;14(23):6013. doi: 10.3390/cancers14236013. Cancers (Basel). 2022. PMID: 36497493 Free PMC article.
12 results